+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 13 Actively Recruiting clinical trials

L

Actively Recruiting

This research evaluates the long-term safety and tolerability of LB-102 in adults with stable schizophrenia who are experiencing inadequate response or side effects from their current antipsychotic medications, or who have completed earlier LB-102 studies. It is a Phase 3, open-label, multicenter study focusing on patients who wish to change medications or continue treatment with LB-102. Participants receive LB-102 with flexible dosing ranging from 50 mg to 100 mg. The study is open-label, meaning all participants receive the study drug without a placebo comparison. The treatment period lasts 52 weeks, during which researchers monitor safety and tolerability. Throughout the study, participants are closely assessed for adverse events and treatment-emergent events to evaluate safety. Effectiveness is also measured using the Positive and Negative Syndrome Scale PANSS. The study duration is one year, during which participants undergo regular evaluations to track their response and monitor any side effects.

Age: 18Years - 65YearsAll GendersPhase 3
23 locations
W

Actively Recruiting

Bipolar disorder is a serious, long-lasting mood condition affecting both adults and children. This research focuses on studying the effects and safety of cariprazine, a medication approved for adults, in treating depressive episodes linked to bipolar I disorder in children and adolescents aged 10 to 17. The study aims to better understand how this drug impacts the pediatric population, where treatment options are currently limited. Participants will be randomly assigned to one of two groups one receiving cariprazine at flexible doses adjusted by age and weight, and the other receiving a placebo. The treatment lasts six weeks, with dose adjustments at week 3 depending on response. Following treatment, there is a four-week safety follow-up period. Weekly visits at clinics or hospitals will support monitoring and treatment. During the study, participants will undergo medical assessments, blood tests, questionnaires, and side effect checks to evaluate the drugs impact. Researchers will track changes in mood symptoms using scales like the Childrens Depression Rating Scale and monitor safety through vital signs, lab tests, and movement assessments. The total study participation spans around 10 weeks, including treatment and follow-up.

Age: 10Years - 17YearsAll GendersPhase 3
81 locations
L

Actively Recruiting

Researchers are studying the long-term safety and tolerability of KarXT for treating mania or mania with mixed features in adults with Bipolar-I disorder. This phase 3 open-label extension trial focuses on participants who have either completed prior related studies or are newly diagnosed with specific criteria. The study aims to monitor adverse events and changes in symptoms over an extended period. Participants receive KarXT at specified doses, with some possibly receiving additional therapeutic doses of Lithium, Valproate, or Lamotrigine. The study does not involve placebo and is designed as a single-group intervention. The treatment and monitoring continue for up to 54 weeks, focusing on safety and symptom assessments. During the study, participants undergo regular evaluations including psychiatric assessments and safety monitoring. Researchers track treatment-emergent adverse events, serious adverse events, and changes in suicidal ideation using the Columbia-Suicide Severity Rating Scale. Additional assessments include rating scales for movement disorders and urinary symptoms. The total participation period extends up to about one year, with ongoing safety and tolerability evaluations.

Age: 18Years - 65YearsAll GendersPhase 3
184 locations
E

Actively Recruiting

Researchers are evaluating DT-101 as a potential treatment for adults with Major Depressive Disorder MDD. This study compares the effects of DT-101 to a placebo to understand how it may impact depression symptoms. The study also aims to assess the safety and tolerability of DT-101 in this population. Participants will be randomly assigned to receive one of two versions of DT-101 or a placebo. The study involves physical and neurological exams, blood and urine sample collection, and clinical assessments. Blood samples will also be analyzed to study how DT-101 is absorbed and processed by the body and to explore genetic factors that may influence response to the drug. Throughout the study, participants will attend clinic visits approximately every two weeks for health checks and to complete questionnaires about their depression. Researchers will monitor changes in depression severity using the Montgomery sberg Depression Rating Scale MADRS and other clinical measures over 42 days. Safety and ongoing suitability for participation will be regularly evaluated, with the total study duration extending up to about six weeks.

Age: 18Years - 75YearsAll GendersPhase 2
43 locations
E

Actively Recruiting

Researchers are evaluating the effectiveness and safety of adding KarXT to existing treatments for mania in adults with Bipolar-I Disorder. This trial focuses on participants experiencing an acute manic episode, with or without mixed features, who are already taking lithium, valproate, or lamotrigine. The study aims to improve mania symptoms, measured by changes in the Young Mania Rating Scale after five weeks. Participants will be randomly assigned to receive either KarXT in addition to their mood stabilizer or a placebo plus their mood stabilizer. The treatments are given in specified doses over the study period, with careful monitoring of side effects and other health measures. The study includes a double-blind design, meaning neither participants nor researchers know which treatment is given to ensure unbiased results. During the trial, participants will undergo regular assessments including psychiatric evaluations, rating scales for mania and other symptoms, and safety monitoring up to seven weeks. Researchers will track symptom changes, treatment responses, and any adverse events. Participants are involved in scheduled visits for evaluations and to maintain stable mood stabilizer doses. The total participation lasts until the primary outcome is measured at week five, with additional safety follow-up up to week seven.

Age: 18Years - 65YearsAll GendersPhase 3
109 locations
E

Actively Recruiting

Researchers are evaluating the efficacy and safety of KarXT for treating manic episodes in adults with Bipolar-I Disorder. This Phase 3, randomized, double-blind, placebo-controlled study focuses on adults experiencing an acute episode of mania or mania with mixed features. The study aims to compare KarXT to placebo during a 3-week inpatient treatment period to assess symptom improvement. Participants will be randomly assigned to receive either KarXT or a placebo with flexible dosing during the 3-week inpatient phase. Prior to treatment, participants must undergo a screening period and psychotropic medications must be washed out within 14 days before starting. After the treatment phase, there is a safety follow-up period, with the entire study lasting no more than seven weeks. During the study, participants will be hospitalized for close monitoring. Researchers will assess symptoms using the Young Mania Rating Scale and Clinical Global Impressions-Bipolar at baseline and week 3. Safety evaluations will continue through follow-up visits. The main outcome is the change in mania symptoms after 3 weeks of treatment, with additional measures of clinical response and safety observed throughout the study.

Age: 18Years - 65YearsAll GendersPhase 3
74 locations
L

Actively Recruiting

Researchers are evaluating the long-term safety of two drugs, Deucravacitinib and Ustekinumab, in adults with moderate-to-severe plaque psoriasis who are candidates for phototherapy or systemic treatments. This study is designed to compare these treatments over an extended period, focusing on cardiovascular health and other safety outcomes. The study is sponsored by Bristol-Myers Squibb and is a Phase 3b4 randomized, open-label trial. Participants are randomly assigned to receive either Deucravacitinib or Ustekinumab at specified doses on scheduled days. The study spans up to 5 years, during which participants will be monitored closely for cardiovascular events and other safety outcomes. Treatment adherence and effects will be regularly assessed throughout this long-term safety study. During the study, participants will undergo various evaluations including monitoring for major cardiovascular events such as heart attacks and strokes, other cardiovascular complications, and laboratory assessments including liver function and lipid panels. Researchers will also track serious adverse events and overall mortality up to 60 days after the last dose. This comprehensive monitoring ensures participant safety and gathers essential data on the long-term effects of the treatments over the studys duration, which lasts until January 2031.

Age: 40Years +All GendersPhase 3
411 locations
P

Actively Recruiting

Researchers are evaluating the efficacy and safety of LB-102 in treating adult patients with Bipolar I Disorder who are currently experiencing a major depressive episode. This Phase 2, randomized, double-blind, placebo-controlled multicenter study aims to compare the effects of LB-102 against a placebo over a treatment period of six weeks. Participants will be randomly assigned in equal numbers to receive either LB-102 or a placebo once daily by mouth. LB-102 dosing starts at 25 mg daily for the first three weeks, with a possible increase to 50 mg daily from Week 4 based on clinical assessment scores. Patients on placebo will take one tablet daily for six weeks. Medication will be provided in weekly bottles, and both patients and study staff will be unaware of the treatment assignments. After completing the study treatment on Day 43, participants may resume antidepressant or mood stabilizer treatments if applicable. During the study, participants will undergo several assessments including measurement of depressive symptoms using the Montgomery sberg Depression Rating Scale MADRS-10 from baseline to Day 42. Researchers will also monitor adverse events and treatment-emergent mania symptoms using the Young Mania Rating Scale YMRS up to Day 56. The study includes regular visits for medication dispensing and clinical evaluations over the six-week treatment period, with participant health and safety closely observed throughout.

Age: 18Years - 65YearsAll GendersPhase 2
26 locations
P

Actively Recruiting

The trial investigates the use of KarXT XanomelineTrospium Chloride for preventing relapse in adults diagnosed with schizophrenia. Participants must have had schizophrenia for at least one year with recent hospitalization and persistent symptoms, evaluated by specific psychiatric scales. This Phase 3 randomized, double-blind, placebo-controlled study aims to assess how well KarXT maintains symptom control compared to placebo. Participants are randomly assigned to receive either KarXT or a placebo with specified doses given on set days. The study monitors participants over a period of up to approximately 43 weeks after randomization to evaluate relapse prevention. All treatments and follow-ups are masked to ensure unbiased assessment. During the study, participants undergo regular evaluations including psychiatric assessments using PANSS and CGI-S scores to measure symptom severity and relapse events. Safety is monitored through tracking of adverse events and special interest symptoms. The primary outcome measures the time from randomization to the first relapse. The total participation duration spans several months, with ongoing safety and efficacy assessments throughout the study period.

Age: 18Years - 65YearsAll GendersPhase 3
54 locations
P

Actively Recruiting

Healthy Volunteer

Researchers are evaluating the safety and effect of Brilaroxazine in adults aged 18 to 65 with acute schizophrenia. This Phase 3, randomized, double-blind, placebo-controlled study aims to compare fixed doses of Brilaroxazine to placebo over a short-term period and to assess its long-term safety in stable schizophrenia. The research is sponsored by Reviva Pharmaceuticals and includes both initial treatment and extended observation phases. Participants receive either 15 mg or 50 mg of Brilaroxazine once daily for 28 days under double-blind conditions, or a matching placebo. This is followed by an open-label phase lasting 52 weeks where doses of Brilaroxazine are flexibly adjusted between 15 mg and 50 mg daily. The long-term phase includes subjects who completed the initial double-blind treatment and new participants with stable schizophrenia. Throughout the 56-week study, participants undergo regular assessments to monitor safety and effectiveness. Researchers measure outcomes during the initial 28 days and the subsequent 52-week open-label period. The study includes various evaluations, including safety monitoring and symptom assessments, to gather comprehensive data on Brilaroxazines impact during both acute and stable phases of schizophrenia treatment.

Age: 18Years - 65YearsAll GendersPhase 3
18 locations

1-10 of 13

1